Q-omics provides the consensus-scored PHBP13 profile across patient tissues and cancer cell-line models. PHBP13 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PHBP13 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PHBP13 RNA expression shows 11,048 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UCEC, KIRC, and LAML as cancer lineages where PHBP13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP13 survival associations across molecular data types. PHBP13 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP13 RNA expression–survival associations across cancer types. High PHBP13 expression shows unfavorable associations in UCEC, KIRP, LIHC and ACC, but favorable associations in PAAD and THYM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PHBP13 RNA expression.
This table summarizes PHBP13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP13 shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, BRCA, KIRP and LIHC. The KIRC box plot shows higher PHBP13 RNA expression in tumor versus normal tissue (log2 FC = +0.268, t-test p < 0.001).
This table shows molecular features associated with PHBP13 in patient tissues and cancer cell lines. In patient samples, PHBP13 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
